Sectors
APGE
Apogee Therapeutics, Inc.
134.09
1 x 133.85
3 x 134.13
bid
ask
-
0.21
0.16%
1 @ 07:34 PM
134.13 +0.04 (0.03%)
| Ytd | 77.65% | |
| 1y | 250.47% |
134.05
day range
134.35
34.65
52 week range
134.30
| Open | 134.25 | Prev Close | 134.30 | Low | 134.05 | High | 134.35 | Mkt Cap | 8.30B |
| Vol | 1.74M | Avg Vol | 2.59M | EPS | -4.33 | P/E | -30.97 | Forward P/E | -25.76 |
| Beta | 0.33 | Short Ratio | 0.94 | Inst. Own | 109.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 111.65 | 200-d Avg | 82.53 | 1yr Est | 130.53 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-10 | 2026-06 | -1.07 | N/A | N/A | N/A |
| 2026-05-11 | 2026-03 | -1.07 | -1.06 | 0.01 | 0.93% |
| 2026-03-02 | 2025-12 | -1.05 | -1.03 | 0.02 | 1.90% |
| 2025-11-10 | 2025-09 | -1.12 | -1.11 | 0.01 | 0.89% |
| 2025-08-11 | 2025-06 | -1.03 | -1.13 | -0.1 | -9.71% |
| 2025-05-12 | 2025-03 | -1.19 | -0.95 | 0.24 | 20.17% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-24 | Stifel | Downgrade | Buy | Hold |
| 2026-06-24 | TD Cowen | Downgrade | Buy | Hold |
| 2026-06-24 | Guggenheim | Downgrade | Buy | Neutral |
| 2026-06-24 | Mizuho | Downgrade | Outperform | Neutral |
| 2026-06-23 | Deutsche Bank | Downgrade | Buy | Hold |
| 2026-06-23 | Citigroup | Downgrade | Buy | Neutral |
Profile
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-30 | DAMBKOWSKI CARL | Officer | 177.87K | Sale |
| 2026-01-21 | FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | 0.00 | Sale |
| 2026-04-30 | HENDERSON JANE | Chief Financial Officer | 173.37K | Sale |
| 2026-07-09 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 920.94K | Stock Gift |
| 2024-12-11 | MCKENNA MARK C | Director | 20.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Investment Management,Inc. | 10.30M | 0.00 | 15.06% |
| 2026-03-30 | FMR Inc | 9.26M | 0.00 | 13.54% |
| 2026-03-30 | VR Adviser, LLC | 8.49M | 0.00 | 12.42% |
| 2026-03-30 | Wellington Management Company LLP | 4.38M | 0.00 | 6.40% |
| 2026-03-30 | BlackRock Inc | 4.09M | 0.00 | 5.97% |
| 2025-12-30 | Vanguard Group Inc | 2.86M | 0.00 | 4.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Growth Compy Commingled Pl S | 2.59M | 0.00 | 3.78% |
| 2026-03-30 | Vanguard Health Care Inv | 1.91M | 0.00 | 2.79% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 1.87M | 0.00 | 2.74% |
| 2026-05-30 | Fidelity Growth Company Fund | 1.84M | 0.00 | 2.69% |
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 1.20M | 0.00 | 1.75% |
| 2026-06-29 | iShares Russell 2000 ETF | 1.16M | 0.00 | 1.70% |